In its latest setback, Merck has announced ... in combination with Astellas/Pfizer’s Xtandi (enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC) – its last remaining ...

A US district court has said that a key patent held by Astellas on its Myrbetriq drug for urinary incontinence is invalid, in a setback ... for Pfizer-partnered prostate cancer therapy Xtandi ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

The FDA approved the poly ADP ribose polymerase (PARP) inhibitor in June 2023 in combination with enzalutamide for men with ...

Cancer remains one of the biggest health challenges of our lifetime. Millions of people globally receive a cancer diagnosis each year — in the United States, that’s about one diagnosis every 30 ...

Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on ...

We therefore did not pursue these models further. Fig 1. Predicted cumulative prostate cancer risks for a 45-year-old consultand by (A) father's age at prostate cancer diagnosis, (B) brother's age at ...

Story May 27 - Boundless Bio: After a phase 1/2 trial revealed shortcomings for Boundless’ lead cancer candidate ... that the biotech and partner Pfizer are dropping two phase 3 trials from ...